Usage of Newer Immunotherapies in Myasthenic Crisis – A Review of the Literature
DOI:
https://doi.org/10.17161/rrnmf.v5i2.22315Abstract
none
Metrics
Downloads
References
Phillips LH, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 1996;47(5):1233–8.
Grob D, Arsura EL, Brunner NG, Namba T. The Course of Myasthenia Gravis and Therapies Affecting Outcomes. Annals of the New York Academy of Sciences 1987;505(1):472–99.
Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis. Neurologic Clinics 2018;36(2):253–60.
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Neurology 2016;87(4):419–25.
Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 2009;72(18):1548–54.
Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist 2011;1(1):16–22.
Geng Y, Zhang H, Wang Y. Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients: A meta-analysis. Medicine (Baltimore) 2020;99(1):e18622.
Nelke C, Schroeter CB, Stascheit F, et al. Eculizumab versus rituximab in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry 2022;93(5):548–54.
Claytor B, Cho S-M, Li Y. Myasthenic crisis. Muscle & Nerve 2023;68(1):8–19.
Vanoli F, Mantegazza R. What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis? Expert Opinion on Pharmacotherapy 2022;23(13):1471–4.
Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 2019;12:1756286419832242.
Suzuki S, Uzawa A, Murai H. Efgartigimod for generalized myasthenia gravis with or without anti-acetylcholine receptor antibodies: a worldwide and Japanese perspective. Expert Rev Clin Immunol 2022;18(12):1207–15.
Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 2017;16(12):976–86.
Meisel A, Annane D, Vu T, et al. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol 2023;270(8):3862–75.
Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2021;20(7):526–36.
Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Neurology 2023;22(5):395–406.
Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 2023;22(5):383–94.
Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid 2022;1(5):EVIDoa2100066.
Kim MS, Prasad V. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. JAMA Intern Med 2020;180(2):315–7.
Uysal SP, Morren JA. Promising therapies for the treatment of myasthenia gravis. Expert Opinion on Pharmacotherapy 2024;0(0):1–14.
Peter H-H, Ochs HD, Cunningham-Rundles C, et al. Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. J Allergy Clin Immunol 2020;146(3):479-491.e5.
Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29(4):319–29.
Crew PE, McNamara L, Waldron PE, McCulley L, Jones SC, Bersoff-Matcha SJ. Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease. J Infect 2020;80(3):350–71.
Crew PE, Abara WE, McCulley L, et al. Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series. Clin Infect Dis 2018;10.1093/cid/ciy958.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Yuebing Li, Johnny Dang, Sanem Uysal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
